	US 12,435,153 B2
	Antibody targeting B cell maturation antigen and related products thereof and medical applications
Zhihua Lu, Beijing (CN); and Yongfeng Liu, Beijing (CN)
Assigned to Beijing Gene MiNK Biotechnology CO.LTD, Beijing (CN)
Filed by Beijing Gene MINK Biotechnology CO.LTD, Beijing (CN)
Filed on Sep. 30, 2024, as Appl. No. 18/901,182.
Claims priority of application No. 202311289005.6 (CN), filed on Oct. 8, 2023.
Prior Publication US 2025/0115674 A1, Apr. 10, 2025
Int. Cl. A61K 39/395 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); G01N 33/68 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); G01N 33/6854 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01); G01N 2333/70578 (2013.01)]

18 Claims

1. An antibody or an antigen binding fragment thereof targeting a B cell maturation antigen (BCMA), the antibody containing a variable light chain and a variable heavy chain,

the variable light chain containing a light chain complementarity-determining region (CDR) 1, a light chain CDR2, and a light chain CDR3, the light chain CDR1 having the sequence as shown in SEQ ID NO. 1, the light chain CDR2 having the amino acid sequence as shown in SEQ ID NO. 2, and the light chain CDR3 being as shown in SEQ ID NO. 3 or SEQ ID NO. 4; and

the variable heavy chain containing a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, the heavy chain CDR1 having the sequence as shown in SEQ NO. 5, the heavy chain CDR2 having the amino acid sequence as shown in SEQ ID NO. 6, and the heavy chain CDR3 being as shown in SEQ ID NO. 7 or SEQ ID NO. 8.